奥沙利铂联合卡培他滨方案治疗晚期胃癌的临床观察  

The Clinical Observation of Oxaliplatin in Combination with Capecitabine in Patients with Advanced Gastric Cancer

作　　者：胡伟民[1] 王进[1] 

机构地区：[1]广州医学院附属肿瘤医院,510095

出　　处：《实用癌症杂志》2007年第1期53-54,66,共3页The Practical Journal of Cancer

摘　　要：目的 观察奥沙利铂联合卡培他滨方案治疗晚期胃癌的疗效及安全性。方法 对35例晚期胃癌患者采用奥沙利铂100mg／m^2，静脉滴注，第1天；卡培他滨2000mg／m^2／d分早晚2次餐后口服，第1—14天。每3周重复。每周期评价疗效同时记录不良反应。结果 全组35例病例中CR2例（5．71％），PR13例（37．14％），SD10例（28、57％），PD10例（28、57％），总有效率为42、86％。主要不良反应为中性粒细胞减少、手足综合症、腹泻、皮肤色素沉着．无治疗相关死亡。结论 奥沙利铂联合卡培他滨方案治疗晚期胃癌，疗效确切，多数患者耐受良好，值得进一步研究。Objective To evaluate the efficacy and safety of Oxaliplatin in combination with capecitabine in treating advanced gastric cancer. Methods Thirty-five patients with advanced gastric cancer received chemotherapy： Oxaliplatin 100 mg/ m^2 i. v,dl ; combining oral capecitabine 2000mg/m^2. d （divided in two doses） d1-14; and repeated every 3 weeks. The efficacy and safety were assessed in every cycle. Results 2 cases （ 5.71% ） achieved CR, 13 cases （ 37. 14% ） had PR, 10 cases （8.57%） had SD, 10 cases （28.57%） had PD ,with an overall response rate of 42.86%. The most common adverse effects were leucopenia, hand-foot syndrome, diarrhea and skin pigmentation. There was no treatment-related death. Conclusion Chemotherapy with oxaliplatin combined with capecitabine is effective and well-tolerated to the patients with advanced gastric cancer.

关 键 词：胃肿瘤 联合化疗 奥沙利铂 卡培他滨 

分 类 号：R735.2[医药卫生—肿瘤]